|Bid||1.4900 x 0|
|Ask||1.4950 x 0|
|Day's Range||1.4850 - 1.5300|
|52 Week Range||1.0150 - 2.4700|
|Beta (3Y Monthly)||2.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Silviu Itescu became the CEO of Mesoblast Limited (ASX:MSB) in 2011. First, this article will compare CEO compensa...
Mesoblast Limited's (ASX:MSB): Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. With the latest financial year loss of -US$35.3m and a trailing-twelve month of -US$86.1m, the AU$624mRead More...
If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Mesoblast Limited’s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.8m and a trailing-twelve month of -US$41.6m, the AU$750.5m market-cap alleviates its loss by movingRead More...
Mesoblast (NASDAQ: MESO ) releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Mesoblast's Q4 earnings report. Earnings and Revenue Analysts are predicting Mesoblast will ...
July 17 (Reuters) - Tasly Pharmaceutical Group Co Ltd : * SAYS IT SIGNS AGREEMENT TO INVEST $20 MILLION IN AUSTRALIA'S MESOBLAST LIMITED Source text in Chinese: https://bit.ly/2L387MD Further company coverage: ...
The Australian company unveiled data from a study evaluating a potential treatment for children with steroid refractory acute Graft Versus Host Disease.